NewAmsterdam reported FY 2025 revenue of USD 22.5 million and a net loss of USD 203.8 million. R&D expenses were USD 141.8 million and SG&A expenses were USD 106.4 million. Cash, cash equivalents and marketable securities totaled USD 728.9 million at Dec. 31, 2025. On the business side, NewAmsterdam said marketing authorization applications for obicetrapib 10 mg and the obicetrapib/ezetimibe fixed-dose combination were accepted for review by the EMA, UK and Switzerland regulators, with approval decisions expected in 2H 2026, as the company and partner Menarini prepare for a potential European launch. The company also highlighted progress across its Phase 3 program, including PREVAIL (over 9,500 patients enrolled; blinded event-rate tracking in line with BROADWAY), REMBRANDT (enrollment expected to complete for ~300 patients in 2026), and RUBENS (initiated in Dec. 2025; topline data expected by year-end 2026), and said it plans to initiate a new trial of obicetrapib in early Alzheimer’s disease patients in 2026 following biomarker findings from BROADWAY.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656503-en) on February 18, 2026, and is solely responsible for the information contained therein.